The Recall Desk
ModerateFDA (Drugs)·D-0137-2024·Announced 2023-12-13

Bupropion Hydrochloride Extended-Release Tablets Recalled for Failed Dissolution

Sun Pharmaceutical is recalling Bupropion Hydrochloride Extended-Release Tablets 200 mg due to failed dissolution specifications. The recall affects 2,016 bottles with lot HAD0630A distributed nationwide.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: FDA Class III recall with no reported illnesses or injuries. While failed dissolution could affect medication efficacy, the hazard is theoretical rather than documented. Class III recalls without reported adverse events typically score 1-2; Moderate reflects the potential impact on drug delivery.

Plain-English summary

Sun Pharmaceutical Industries Inc is recalling Bupropion Hydrochloride Extended-Release Tablets, USP 200 mg due to failed dissolution specifications. The recall affects 2,016 bottles with lot number HAD0630A (expiration date 1/2024) distributed nationwide.

Dissolution specifications are FDA requirements that ensure medications dissolve and are absorbed into the body at the intended rate. When tablets fail to meet these specifications, the drug's delivery to patients may be affected.

Bupropion Hydrochloride is a prescription antidepressant used to treat depression. Patients who have received this product should contact their healthcare provider or pharmacist for guidance.

The recalled product

Product
BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE)
Brand
BUPROPION HYDROCHLORIDE
Manufacturer
SUN PHARMACEUTICAL INDUSTRIES INC
Hazard
  • dissolution-failure

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot HAD0630A
  • exp 1/2024

UPCs (2)

  • 0347335738865
  • 0347335737868

Distribution

Distributed nationwide across the United States.